Log In
Print this Print this

cixutumumab (IMC-A12, LY3012217)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionHuman mAb against insulin-like growth factor-1 (IGF-1) receptor (IGF1R)
Molecular Target Insulin-like growth factor-1 (IGF-1) receptor (IGF1R) (CD221)
Mechanism of ActionInsulin-like growth factor-1 (IGF-1) receptor inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today